Surveillance and management of multidrug-resistant microorganisms

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 8, 2011, Pages 653-679

  Orsi, Giovanni Battista ^a   Falcone, Marco ^a   Venditti, Mario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

carbapenem resistant Acinetobacter baumannii; carbapenem resistant Enterobacteriaceae; carbapenem resistant Pseudomonas aeruginosa; glycopeptide resistance; infection control; management; microorganisms; MRSA; multidrug resistant; surveillance; VRE

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; AVOPARCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFAZOLIN; CEFOTAXIME; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CEPHALOSPORIN; CLINDAMYCIN; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; NAFCILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; STREPTOMYCIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM DETECTION; BLOODSTREAM INFECTION; BONE INFECTION; BRAIN VENTRICULITIS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; CONTACT EXAMINATION; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; DISEASE SURVEILLANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ENTEROBACTERIACEAE; ENTEROCOCCAL INFECTION; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION CONTROL; INFECTION RISK; INFECTIOUS ARTHRITIS; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PNEUMONIA; PROSTHESIS INFECTION; PSEUDOMONAS AERUGINOSA; REVIEW; SAMPLING; SKIN DECONTAMINATION; SKIN INFECTION; SOFT TISSUE INFECTION; STANDARD; STAPHYLOCOCCUS INFECTION; THROMBOPHLEBITIS; TREATMENT PLANNING; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INFECTION CONTROL; MICROBIAL SENSITIVITY TESTS; PUBLIC HEALTH; PUBLIC HEALTH SURVEILLANCE; RISK FACTORS;

EID: 80051763692     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.77     Document Type: Review

References (315)

1. Curcio D, Fernandez F, Vergara G, Vazquez W, Luna CM. Late-onset ventilator-associated pneumonia due to Acinetobacter spp: Experience with tigecycline. J. Chemother. 29, 58-62 (2009).
2. Curcio D. Tigecycline for severe infections: The gap between the warning and the necessity. J. Antimicrob. Chemother. 66(2), 454-456 (2011).
3. Loeffler CA, MacDougall C. Update on prevalence and treatment of methicillin resistant Staphylococcus aureus infections. Expert Rev. Anti Infect. Ther. 55, 961-981 (2008).
4. Pantosti A, Venditti M. What is MRSA? Eur. Respir. J. 34, 1190-1196 (2009).
5. Rossolini GM, Mantengoli E, Montagnani F, Pollini S. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Curr. Opin. Microbiol. 13(5), 582-588 (2010).
6. Hidron AI, Edwards JR, Patel J et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the national healthcare safety network at centers for disease control and prevention 2006-2007. Infect. Control Hosp. Epidemiol. 29, 996-1011 (2008).
7. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5, 2 (2006).
8. Kobayashi H. National hospital infection surveillance on methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 60, 172-175 (2005). (Pubitemid 40590587)
9. Collignon P, Nimmo GR, Gottlieb T, Gosbell IB. Australian Group on Antimicrobial Resistance. Staphylococcus aureus bacteremia, Australia. Emerg. Infect. Dis. 11, 554-561 (2005).
10. Rosenthal VD, Maki DG, Jamulitrat S et al. International nosocomial infection control consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am. J. Infect. Control 38(2), 95-104 (2010).
11. Zhanel GG, DeCorby M, Laing N et al. Antimicrobial-resistant pathogens in intgensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob. Agents Chemother. 52(4), 1430-1437 (2008). (Pubitemid 351522009)
12. Gorwitz RJ, Kruszon-Moran D, McAllister SK et al. Changes in the prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2004. J. Infect. Dis. 197, 1226-1234 (2008). (Pubitemid 351632753)
13. Kluytmans-VandenBergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: Current perspectives. Clin. Microbiol. Infect. 12(Suppl. 1), 9-15 (2006).
14. Jansen WTM, van der Bruggen JT, Verhoef J, Fluit AC. Bacterial resistance: A sensitive issue complexity of the challenge and containment strategy in Europe. Drug Resis. Updat. 9, 123-133 (2006). (Pubitemid 44279521)
15. Ratnaraja NVDV, Hawkey PM. Current challenges in treating MRSA: What are the options? Expert Rev. Anti Infect. Ther. 6, 601-618 (2008).
16. Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352, 1436-1444 (2005).
17. Millar BC, Loughrey A, Elborn JS, Moore JE. Proposed definitions of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). J. Hosp. Infect. 67, 109-113 (2007). (Pubitemid 47534958)
18. Elston JW, Barlow GD. Community-associated MRSA in United Kingdom. J. Infect. 59(3), 149-155 (2009).
19. Harbarth S, Francois P, Schrenzel J et al. Community-associated methicillin-resistant Staphylococcus aureus, Switzerland. Emerg. Infect. Dis. 11, 962-965 (2005). (Pubitemid 40720864)
20. Orsi GB, Mastroianni CM, Giordano A, Monaco M, Venditti M. Lack of community-associated MRSA in Rome. J. Hosp. Infect. 71(4), 374-376 (2009).
21. Witte W. Community acquired methicillin-resistant Staphylococcus aureus: What do we need to know? Clin. Microbiol. Infect. 15(Suppl.), 17-25 (2009).
22. Otter JA, French GL. Molecular epidemiology of community-associated mehicillin-resistant Staphylococcus aureus in Europe. Lancet Infect. Dis. 10, 227-239 (2010).
23. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46, S344-S349 (2008). (Pubitemid 351717321)
24. Chini V, Petinaki E, Meugnier H et al. Emergence of a new clone carrying Panton-Valentine leukocidin genes and staphylococcal cassette chromosome mec type V among methicillin-resitant Staphylococcus aureus in Greece. Scand. J. Infect. Dis. 40(5), 368-372 (2008). (Pubitemid 351566563)
25. Seybold U, Kourbatova EV, Johnson JG et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated bloodstream infections. Clin. Microbiol. Infect. 42, 647-656 (2006). (Pubitemid 43271378)
26. Valsesia G, Rossi M, Bertschy S, Pfyffer GE. Emergence of SCCmec type IV and SCCmec type V methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leukocidin genes in a large academic teaching hospital in central Switzerland: External invaders or persisting circulators? J. Clin. Microbiol. 48(3), 720-727 (2010).
27. McCarthy NL, Sullivan PS, Gaynes R, Rimland D. Healthcare associated and community-associated methicillin-resistant Staphylococcus aureus infections: A comparison of definitions. Am. J. Infect. Control 38(8), 600-606 (2010).
28. Nichol KA, Adam HJ, Hussain Z et al. comparison of community-associated asnd healthcare-associated methicillin-resistant Staphylococcus aureus in Canada: Results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 69(3), 320-325 (2011).
29. Park SH, Park C, Yoo JH et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated bloodstream infections in Korea. Infect. Control Hosp. Epidemiol. 30(2), 146-155 (2009).
30. Milstone AM, Carroll KC, Ross T, Shangraw KA, Perl TM. Community-associated methicillin-resistant Staphylococcus aureus strains in pediatric intensive care unit. Emerg. Infect. Dis. 16(4), 647-655 (2010).
31. Rupp ME, Fey PD. Staphylococcus epidermidis and other coagulase negative staphylococci. In:Principles and Practice of Infectious Diseases. 7th Edition. Mandell GP, Bennett JE, Dolin R (Eds). Churchill Livingstone Elsevier, PA, USA, 2579-2589 (2010).
32. Nathwani D. Health economia issues in the treatment of drug-resistant serious Gram-positive infections. J. Infect. 59(S1), S40-S50 (2009).
33. Shorr AF. Epidemiology and economic impact of methicillin-resistant Staphylococcus aureus. Pharmacoeconomics 25(9), 751-768 (2007). (Pubitemid 47481640)
34. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. the impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay and hospital charges. Infect. Control Hosp. Epidemiol. 26(2), 166-174 (2005). (Pubitemid 40445022)
35. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 52, 113-122 (2005). (Pubitemid 40826937)
36. Shorr AF, Lodise T. Burden of methicillin-resistant Staphylococcus aureus on healthcare cost and resource utilization. ISMR Update 1, 4-11 (2006).
37. Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K. Excess costs for utilization with methicillin resistance for patients with Staphylococcus aureus infection. Infect. Control Hosp. Epidemiol. 31, 365-373 (2010).
38. Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: A multi-center matched outcomes study. PloS ONE 4(12), e8305 (2009).
39. Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, Pallesen LV. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin. Microbiol. Infect. 13, 257-263 (2007). (Pubitemid 46603355)
40. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15), 1763-1771 (2007). (Pubitemid 47598444)
41. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: Risk factors, outcomes and influence of methicillin resistance in Calgary, Canada, 2000-2006. J. Infect. Dis. 198, 336-343 (2008).
42. Naber CK. Staphylococcus aureus bacteremia: Epidemiology, pathophisiology and management strategies. Clin. Infect. Dis. 48, 231-237 (2009).
43. Uslan DZ, Crane SJ, Steckelberg JM, Cockerill FRJr, St Sauver JL, Stoner S. Age and sex associated trends in bloodstream infection: A population-based study in Olmsted County, Minnesota. Arch. Intern. Med. 49(18), 1851-1859 (2007).
44. Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit. Care Med. 34, 700-706 (2006).
45. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchamer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin. Infect. Dis. 36, 53-59 (2003). (Pubitemid 36099097)
46. Engemann JJ, Carmeli Y. Cosgrove SE et al. Adverse clinical economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36(5), 592-598 (2003). (Pubitemid 36259564)
47. Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am. J. Med. 121, 310-315 (2008). (Pubitemid 351417832)
48. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: Results from a large US database of culture-positive pneumonia. Chest 128, 3854-3862 (2005). (Pubitemid 43062645)
49. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5), S378-S385 (2008). (Pubitemid 351717325)
50. Niederman MS. Treatment options for nosocomial pneumonia due to MRSA. J. Infect. 59(Suppl. 1), S25-S31 (2009).
51. Haque NZ, Cahuayme Zuniga L, Peyrani P et al. Relationship of vancomycin MIC to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Chest 138(6), 1356-1362 (2010).
52. Francis JS, Doherty MC, Lopatin U et al. severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin. Infect. Dis. 40, 100-107 (2005). (Pubitemid 40053465)
53. Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352, 1445-1453 (2005). (Pubitemid 40471452)
54. Bassetti M, Nicco E, Malgorzata M, Viscoli C, Valbusa A, Bongiorno D. Community associated methicillin resistant Staphylococcus aureus (CA-MRSA) infective endocarditis in Italy. J. Infect. 61(4), 353-355 (2010).
55. Favre B, Hugonnet S, Correa L, Sax H, Rohner P, Pittet D. Nosocomial bacteremia: Clinical significance of a single blood culture positive for coagulase-negative staphylococci. Infect. Control Hosp. Epidemiol. 26, 697-702 (2005). (Pubitemid 41169739)
56. Wang A, Athan E, Pappas PA et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297(12), 1354-1361 (2007). (Pubitemid 46513236)
57. Chu VH, Woods CW, Miro JM et al. Emergence of coagulase negative staphylococci as a cause of native valve endocarditis. Clin. Infect. Dis. 46(2), 232-242 (2008). (Pubitemid 351269162)
58. Stryjewski ME, Szczech LA, Benjamin DK Jr et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44(2), 190-196 (2007). (Pubitemid 46079979)
59. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J. Antimicrob. Chemother. 57(4), 589-608 (2006).
60. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ et al. Clinical Consensus Conference: Survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin. Infect. Dis. 48, S260-S270 (2009).
61. Boucher H, Miller LG, Rozonable RR. Serious infections caused by methcillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 51(Suppl. 2), 183-197 (2010).
62. Lin MY, Hayden MK. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: Recognition and prevention in intensive care units. Crit. Care Med. 38(Suppl.), S335-S344 (2010).
63. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect. Dis. 1, 147-155 (2001). (Pubitemid 33586048)
64. Tenover F, Biddle J, Lancaster M. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7, 327-332 (2001). (Pubitemid 32374355)
65. Sievert DM, Rudrick JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resitant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46, 668-774 (2008).
66. Lalueza A, Vhaves F, San Juan R, Daskalaki M, Otero JR, Aguado JM. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J. Infect. Dis. 201(2), 311-312 (2010).
67. Peleg AY, Pillai S, Mylonakis E, Moellering RC, Eliopoulos GM. Reply to Lalueza A et al. J. Infect. Dis. 201(2), 312-313 (2010).
68. Soriano A, Marco F, Martinez JA. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46, 193-200 (2008). (Pubitemid 351269157)
69. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin. Infect. Dis. 48, 997-998 (2009).
70. Tenover FC, Moellering RC Jr. The rationale of revising the clinical and laboratory standars institute vancomycin minimal inhibitory concentration interpretative criteria for Staphylococcus aureus. Clin. Infect. Dis. 44, 1208-1215 (2007). (Pubitemid 46651246)
71. Appelbaum PC. Reduced glycopeptides susceptibility in methicillin resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 30, 398-408 (2007). (Pubitemid 47498971)
72. Sakoulas G, Moellering RC Jr. Increasing atbiotic resistance among methicillin resistant Staphylococcus aureus strains. Clin. Infect. Dis. 46, S360-S367 (2008). (Pubitemid 351717323)
73. Lodise TP, Graves J, Evans A. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52, 3315-3320 (2008).
74. Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious methicillin-resistant Staphylococcus aureus infections: What are the limits? Int. J. Antimicrob. Agents 37(3), 202-209 (2011).
75. Bongiorno D, Campanile F, Mongelli G et al. DNA methylase modifications and other linezolid resistance mutations in coagulase-negative staphylococci in Italy. J. Antimicrob. Chemother. 65(11), 2336-2340 (2010).
76. Takeuchi F, Watanabe S, Baba T et al. Whole-genome sequencing of Staphylococcus haemolyticus uncovers the extreme plasticity of its genome in evolution of human-colonizing staphylococcal species. J. Bacteriol. 187, 7292-7308 (2005). (Pubitemid 41507785)
77. Raponi G, Ghezzi MC, Gherardi G et al. Antimicrobial susceptibility, biochemical and genetic profiles of Staphylococcus haemolyticus strains from the bloodstream of patients hospitalized in critical care units. J. Chemother. 26, 264-269 (2005). (Pubitemid 40992263)
78. Santos Sanches I, Mato R, de lencastre H, Tomasz A. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase positive and coagulase negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb. Drug Resist. 6, 199-211 (2000).
79. Falcone M, Giannella M, Raponi G, Mancini C, Venditti M. Teicoplanin use and emergence of Staphylococcus haemolyticus: Is there a link? Clin. Microbiol. Infect. 12, 96-97 (2006). (Pubitemid 43372249)
80. Rehm SJ, Tice A. Staphylococcus aureus: Methicillin-susceptible S. aureus to methicillin-resistant S.aureus and vancomycin-resistant S. aureus. Clin. Infect. Dis. 51(S2), S176-S182 (2010).
81. Bonten MJ, Chastre J, Craig WA et al. Guidelines for the management of adults with hospital acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388-416 (2005).
82. Villani P, Regazzi MB, Marubbi F et al. cerebrospinal fluid linezolid concentration in postneurosurgical central nervous system infections. Antimicrob. Agents Chemother. 46, 936-937 (2002). (Pubitemid 34157696)
83. Adembri C, Fallani S, Cassetta MI et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: Intermittent versus continuous infusion. Int. J. Antimicrob. Agents 31(2), 122-129 (2008).
84. Monaco M, Antonucci R, Palange P, Venditti M, Pantosti A. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Emerg. Infect. Dis. 11, 1647-1648 (2005). (Pubitemid 41384367)
85. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: A regulatory perspective using the example of bloodstream infection as an indication. Clin. Infect. Dis. 50(Suppl. 1), S4-S9 (2010).
86. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis of intravascular catheter-related infection: 2009 update by the Infectious Diseases of America. Clin. Infect. Dis. 49, 1-45 (2009).
87. Gudiol F, Aguado JM, Pascual A et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistant Staphylococcus aureus. Enferm. Infecc. Microbiol. Clin. 27(2), 105-115 (2009).
88. Liu C, Bayer A, Cosgrove SE et al. clinical practice guidelines by the infectious Diseases society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adukts and children. Clin. Infect. Dis. 52(3), e18-e55 (2011).
89. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteraemia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355, 653-665 (2006).
90. Saravolatz LD, Stein GE, Johnson LB. Telavancin: A novel lipoglycopeptide. Clin. Infect. Dis. 49, 1908-1914 (2009).
91. Zhanel GG, Calic D, Schweeizer F et al. New lipoglycopeptides: A comparative review of dalbavancin, oritavancin, and telavancin. Drugs 70, 859-886 (2010).
92. Rubinstein E, Lalani T, Corey GR et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin. Infect. Dis. 52(1), 31-40 (2011).
93. Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker endocarditis lead infective endocarditis with telavancin. Antimicrob. Agents Chemother. 54, 5376-5378 (2010).
94. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J. Antimicrob. Chemother. 65, 1315-1316 (2010).
95. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5), S354-S367 (2005). (Pubitemid 41170382)
96. Bazan JA, Martin SI. Ceftaroline fosafamil: A novel broad-spectrum cephalosporin. Drugs Today 46(10), 743-755 (2010).
97. Zhanel CG, Rossnagel E, Nickol K et al. Ceftazidime pharmaco-dynamic activity versus community-associated and healthcare-associated methicillin resistant Staphylococcus aureus, heteroresistant vancomycin intermediate S. aureus, vancomycin intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. J. Antimicrob. Chemother. 66, 1301-1305 (2011).
98. Esposito S, Leone S, Bassetti M et al. Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults. Infection 37, 478-496 (2009).
99. Leone S, Borrè S, Monforte A et al. Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int. J. Infect. Dis. 14(Suppl. 4), S67-S77 (2010).
100. Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J. Infect. 60(6), 440-451 (2010).
101. Jones RN, Yeaman MR, Sakoulas G et al. Failure in clinical treatment of Staphylococcus aureus infection with daptomycin associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemther. 52, 269-278 (2008).
102. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin and linezolid in methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol. 10, 1-6 (2010).
103. Ikeda-Dantsuji T, Hanaki H, Sakai F et al. Linezolid resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan. J. Infect. Chemother. 17(1), 45-51 (2011).
104. Gao W, Chua K, Davies JK et al. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog. 6, e1000944 (2010).
105. Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance; results from 5591 gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 64, 191-201 (2009).
106. Long KS, Poeshlgaard J, C, Schwarz S, Vester B. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50(7), 2500-2505 (2006). (Pubitemid 43993192)
107. Kehrenberg C, Cuny C, Strommenger B, Schwarz S, Witte W. Methicillin-resistant and susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. Antimicrob. Agents Chemother. 53(2), 779-781 (2009).
108. Mendes RE, Deshpande LM, Castanheira M, Dipersio J, Saubolle MA, Jones RN. First report of cfr-mediated resi stance to linezolid in human staphylococcal clinical isolates in the United States. Antimicrob. Agents Chemother. 52, 2244-2246 (2008). (Pubitemid 351758569)
109. Morales G, Picazo JJ, Baos E et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50, 821-825 (2010).
110. Kehrenberg C, Aarestrup PM, Schwarz S. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob. Agents Chemother. 51, 483-487 (2007). (Pubitemid 46185264)
111. Bonilla H, Huband M, Seidel J et al. Multicity out break of linezolid resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin. Infect. Dis. 51, 796-800 (2010).
112. Sánchez-Garcia M, De la Torre MA, Morales G et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303(22), 2260-2264 (2010).
113. Moellering RC Jr. Enterococcus species, Streptococcus bovis and Leuconostoc species. In:Principles and Practice of Infectious Diseases (Volume 1). Mandell GL, Bennett JE, Dolin R (Eds). Elsevier Churchill Livingstone, PA, USA, 2411-5421 (2005).
114. Ziraqzadesh A, Patel R. Vancomycin-resistant enterococci colonization, infection, detection and treatment. Mayo Clin. Proc. 81, 529-536 (2006).
115. Brown DFJ, Brown NM, Cookson BD et al. National glycopeptide-resistant enterococcal bacteraemia surveillance working group report to the Department of Health - August 2004. J. Hosp. Infect. 62, S1-S27 (2006). (Pubitemid 43185853)
116. Hayden MK, Trenholme GM, Schultz JE, Sahm DF. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J. Infect. Dis. 167(5), 1224-1227 (1993). (Pubitemid 23115622)
117. Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin. Microbiol. Infect. 15, 224-231 (2009).
118. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med. 162, 2223-2228 (2002). (Pubitemid 35231592)
119. Salgado CD. The risk of developing a vancomycin-resistant enterococcus bloodstream infection for colonized patients. Am. J. Infect. Control 36, S175, e5-e175, e8 (2008).
120. Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev. Anti Infect. Ther. 6(5), 637-655 (2008).
121. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant Enterococcus infection in the United States. Infect. Control Hosp. Epidemiol. 30, 184-186 (2009).
122. Reik R, Tenover FC, Klein E, McDonald LC. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn. Microbiol. Infect. Dis. 62, 81-85 (2008).
123. Werner G, Coque TM, Hammerum AM. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 13, pii 9046 (2008).
124. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: A report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58, 163-170 (2007). (Pubitemid 46856806)
125. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: A meta-analysis. Infect. Control Hosp. Epidemiol. 24, 690-698 (2003). (Pubitemid 37221342)
126. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: Does vancomycin resistance make a difference? Arch. Intern. Med. 158(5), 522-527 (1998). (Pubitemid 128681613)
127. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay and costs. Infect. Control Hosp. Epidemiol. 24, 251-256 (2003). (Pubitemid 36538136)
128. Hautemaniere A, Hunter PR, Diguio N, Albuisson E, Hartemenn P. A prospective study of the impact of colonization following hospital admission by glycopeptide-resistant enterococci on mortality during a hospital outbreak. Am. J. Infect. Control 37(9), 746-752 (2009).
129. Sakka V, Tsiodras S, Galani L et al. Risk factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin. Microbiol. Infect. 14(1), 14-21 (2008). (Pubitemid 350226565)
130. Diaz Granados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: A meta-analysis. Clin. Infect. Dis. 41, 327-333 (2005). (Pubitemid 41022109)
131. Gavaldà J, Len O, Mirò JM, Munoz P, Montejo M, Alarcòn A. Brief communication: Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann. Intern. Med. 146, 574-579 (2007). (Pubitemid 351650538)
132. Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: What is the evidence? J. Antimicrob. Chemother. 65, 1126-1136 (2010).
133. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J. Chemther. 18, 27-32 (2006).
134. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 13, pii 19044 (2008).
135. Pitout JDD, Laupland KB. Extended-spectrum b-lactamase-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect. Dis. 8, 159-166 (2008). (Pubitemid 351249250)
136. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol. 300(6), 371-379 (2010).
137. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: Changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59, 165-174 (2007). (Pubitemid 47072053)
138. Chia JH, Su LH, Lee MH et al. Development of high-level carbapenem resistance in Klebsiella pneumoniae among patients with prolonged hospitalization and carbapenem exposure. Microb. Drug Resist. 16(4), 317-325 (2010).
139. Garcia-Fernàndez A, Miriagou V, Papagiannitsis CC et al. An ertapenem-resistant extended-spectrum-b-lactamases-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Antimicrob. Agents Chemother. 54(19), 4178-4184 (2010).
140. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemase (KPCs): An emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65, 1119-1125 (2010).
141. Noordman P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9, 228-236 (2009).
142. Grundmann H, Livermore DM, Giske CG et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: Conclusions from a meeting of national experts. Euro Surveill. 15(46), pii 19711 (2010).
143. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect. Dis. 9, 597-602 (2010).
144. Falcone M, Mezzatesta ML, Perilli M et al. VIM-1 metallo-b-lactamase producing Enterobacter cloacae infections and their correlation with clinical outcome. J. Clin. Microbiol. 47, 3514-3519 (2009).
145. Maltezou HC. Metallo-b-lactamases in Gram-negative bacteria: Introducing the era of pan-resistance? Int. J. Antimicrob. Agents 33, 405.e1-7 (2009).
146. Leavitt A, Chmelnitsky I, Ofek I, Carmeli Y, Navon-Venezia S. Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain. J. Antimicrob. Chemother. 65(2), 243-248 (2010).
147. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents 35(3), 240-243 (2010).
148. Brink A, Feldman C, Richards G, Moolman J, Senekal M. Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer. S. Afr. Med. J. 98(8), 586 (2008).
149. Rhee JY, Park YK, Shin JY et al. KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. Antimicrob. Agents Chemother. 54(5), 2278-2279 (2010).
150. Kontopoulou K, Protonotariou E, Vasilakos K et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 b-lactamase resistant to colistin. J. Hosp. Infect. 76(1), 70-73 (2010).
151. Hentscke M, Wolters M, Sobottka I, Rohde H, Aepfelbacher M. ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline. Antimicrob. Agents Chemother. 54(6), 2720-2723 (2010).
152. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev. Pharmacoecon. Outcomes Res. 10(4), 441-451 (2010).
153. Towner KJ. Acinetobacter: An old friend, but a new enemy. J. Hosp. Infect. 73, 355-363 (2009).
154. Grossi P, Dalla Gasperina D. Treatment of Pseudomonas aeruginosa infection in critically ill patients. Expert Rev. Anti Infect. Ther. 4(4), 639-662 (2006). (Pubitemid 44523942)
155. McGowan JE Jr. Resistance in nonfermenting gram-negative bacteria: Multidrug resistance to the maximum. Am. J. Med. 119, S29-S36 (2006). (Pubitemid 43776143)
156. Rice LB. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleve. Clin. J. Med. 74, S12-S20 (2007).
157. Rice LB. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 12, 476-481 (2009).
158. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13(47), pii 19045 (2008).
159. Moffatt GH, Harper M, Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54(12), 4971-4977 (2010).
160. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: A universal threat to public health? Int. J. Antimicrob. Agents 32(2), 106-119 (2008).
161. Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy. Expert Rev. Anti Infect. Ther. 8(1), 71-93 (2010).
162. Crossman IC, Gould VC, Dow JM et al. The complex genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistant determinants. Genome Biol. 9(4), R74 (2008).
163. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 55, 1619-1629 (2006). (Pubitemid 44902023)
164. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother. 52(3), 813-821 (2008). (Pubitemid 351358357)
165. Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect. Control Hosp. Epidemiol. 31(5), 528-531 (2010).
166. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54371 clinical isolates of Gram-negative bacilli: Report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect. 12, 315-321 (2006). (Pubitemid 43337520)
167. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tygecycline evaluation and surveillance trial. J. Infect. 55, 49-57 (2007). (Pubitemid 46900073)
168. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin America collected as part of TEST and the in vitro activity of tigecycline. J. Antimicrob. Chemother. 60, 1018-1029 (2007). (Pubitemid 47617749)
169. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect. Control Hosp. Epidemiol. 24, 284-295 (2003). (Pubitemid 36538142)
170. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect. Dis. 6, 130 (2006).
171. Saeed S, Fakih MG, Riederer K, Shah AR, Khatib R. Interinstitutional and intrainstitutional transmission of a strain of Acinetobacter baumannii detected by molecular analysis: Comparison of pulsed-field gel electrophoresis and repetitive sequence-based polymerase chain reaction. Infect. Control Hosp. Epidemiol. 27, 981-983 (2006). (Pubitemid 44449261)
172. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 42, 692-699 (2006). (Pubitemid 43271386)
173. Karageorgopoulos DR, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: A review of the scientific evidence. J. Antimicrob. Chemother. 62(1), 45-55 (2008). (Pubitemid 351865873)
174. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51(10), 3471-3484 (2007). (Pubitemid 47519332)
175. Sunenshine RH, Wright MO, Maragakis LL et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg. Infect. Dis. 13(1), 97-103 (2007). (Pubitemid 46057843)
176. Richet H, Fournier PE. Nosocomial infections caused by Acinetobacter baumannii: A major threat worldwide. Infect. Control Hosp. Epidemiol. 27(7), 645-646 (2006). (Pubitemid 44271941)
177. Gootz TD, Marra A. Acinetobacter baumannii: An emerging multidrug-resistant threat. Expert Rev. Anti Infect. Ther. 6(3), 309-325 (2008).
178. Falagas ME, Kopteridis P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review of the literature. J. Hosp. Infect. 64, 7-15 (2006). (Pubitemid 44161380)
179. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact. Antimicrob. Agents Chemother. 50(1), 43-48 (2006). (Pubitemid 43042900)
180. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: Assessment of risk factors and clinical impact. Am. J. Med. 119(6), 526, e19-e526, e25 (2006).
181. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 27(9), 893-900 (2006). (Pubitemid 44449245)
182. Maragakis LL. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit. Care Med. 38(Suppl.), S345-S351 (2010).
183. Lee NY, Lee HC, Chang CM, Shih HI, Wu CJ, Ko WC. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect. Control Hosp. Epidemiol. 28(6), 713-719 (2007).
184. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteraemia on patient outcomes. Antimicrob. Agents Chemother. 54(9), 3717-3722 (2010).
185. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: A systematic review of the available evidence. Int. J. Antimicrob. Agents 29, 9-25 (2007). (Pubitemid 44959774)
186. Karageorgopoulos DR, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 8, 751-762 (2008).
187. Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: Case series and literature review. J. Antimicrob. Chemother. 58, 1078-1081 (2006).
188. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii. Emergence of a successful pathogen. Clin. Microbiol. Rev. 21(3), 538-582 (2008).
189. Orsi GB, Franchi C, Giordano A et al. Multidrug resistant Acinetobacter baumannii in an intensive care unit. J. Chemother. 20, 219-224 (2008). (Pubitemid 351797063)
190. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter infections in critically ill patients: A systematic review of matched cohort and case-control studies. Crit. Care 10, R48 (2006).
191. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit. Care Med. 37, 1463-1469 (2009).
192. Micozzi A, Venditti M, Monaco M et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hemathologica malignancies. Clin. Infect. Dis. 31, 705-711, (2000). (Pubitemid 32295490)
193. Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrobial Agents Chemother. 49, 3980-3981 (2005). (Pubitemid 41233066)
194. Borer A, Saidel-Odes L, Riesenberg K et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect. Control Hosp. Epidemiol. 30, 972-976 (2009).
195. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 30, 1180-1185 (2009).
196. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29, 1099-1106 (2008).
197. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob. Agents Chemother. 52(3), 1028-1033 (2008). (Pubitemid 351358384)
198. Zavascki AP, Barth AL, Fernandes JF, Moro AL, Goncalves AL, Goldani LZ. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortalità in the era of metallo-b-lactamase-mediated multidrug resistance: A prospective observational study. Crit. Care 10(4), R114 (2006).
199. Georges B, Conil JM, Dubouix A et al. Risk of emergence of Pseudomonas aeruginosa resistance to b-lactam antibiotics in intensive care units. Crit. Care Med. 34(6), 1636-1641 (2006). (Pubitemid 43810041)
200. Zavascki M, Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: An old, new friend? Eur. J. Clin. Microbiol. Infect. Dis. 29, 127-142 (2010).
201. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious diseases of North America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program of enhance antimicrobial stewardship. Clin. Infect. Dis. 44, 159-177 (2007). (Pubitemid 46084814)
202. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N. Engl. J. Med. 362, 1804-1813 (2010).
203. Orsi GB, Garcigrave;a-Fernàndez A, Giordano A et al. Risk factors and clinical significance of ertapenem resistant Klebsiella pneumoniae in hospitalized patients. J. Hosp. Infect. 78(1), 54-58 (2011).
204. Miriagou V, Cornaglia G, Edelstein M et al. Acquired carbapenemases in Gram-negative bacterial pathogens: Detection and surveillance issues. Clin. Microbiol. Infect. 16, 112-122 (2010).
205. Livermore DM, Meshtaq S Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem resistant Enterobacteriaceae isolates. J. Antimicrob. Agents 66, 48-53 (2011).
206. Livermore DM, Meshtaq S Warner M et al. Activity of NXL104 combinations with ceftazidime and aztreonam against carbapenemase producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55, 390-394 (2011).
207. Livermore DM, Warner M, Mushtaq. What remains against carbapenem-resistant Enetrobacteraceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents 37(5), 415-419 (2011).
208. Li J, Nation RL, Turnidge JD et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6(9), 589-601 (2006).
209. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J. Antimicrob. Chemother. 60, 1206-1215 (2007). (Pubitemid 350168315)
210. Kwa AL, Lim TP, Low JG et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn. Microbiol. Infect. Dis. 60(2), 163-167 (2008).
211. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 53(8), 3430-3436 (2009).
212. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin. Microbiol. Rev. 21(3), 449-465 (2008).
213. Imberti R, Cusati M, Villani P et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138, 1333-1339 (2010).
214. Lu Q, Girardi C, Zhang M et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 54(9), 3702-3707 (2010).
215. Rattanaumpawan P, Lorsutthitham J, Ungprasert P et al. Randomized controlled trial nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J. Antimicrob. Chemother. 65(12), 2645-2649 (2010).
216. Kofteridis DP, Alexopoulo C, Valakis A et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: A matched-control study. Clin. Infect. Dis. 51(11), 1238-1244 (2010).
217. Cascio A, Conti A, Sinardi L et al. Post-neurosufgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int. J. Infect. Dis. 14(7), e572-e579 (2010).
218. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother. 63(4), 775-780 (2009).
219. Metan G, Alp E, Yildiz O et al. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J. Chemother. 22(2), 110-114 (2010).
220. Poulakou G, Kontopidou FV, Paramythiotou E et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J. Infect. 58(4), 273-284 (2009).
221. Gardiner D, Dukart G, Cooper A, Babinchat T. Safety and efficacy of intravenous tigecycline with subjects with secondary bacteremia: Pooled results from eight Phase III clinical trials. Clin. Infect. Dis. 50, 229-238 (2010).
222. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob. Agents Chemother. 55(2), 1162-1172 (2011).
223. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J. Clin. Microbiol. 47(5), 1613 (2009).
224. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: A pharmacokinetic viewpoint. Int. J. Antimicrob. Agents 34, 101-102 (2009).
225. Welte T, Pletz MW. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: Current and future options. Int. J. Antimicrob. Agents 39, 391-400 (2010).
226. Chemaly RF, Hanmod SS, Jiang Y et al. Tigecycline use in cancer patients with serious infections: Report of 110 cases from a single institution. Medicine (Baltimore) 88, 211-220 (2009).
227. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: A drug use evaluation. BMC Infect. Dis. 10, 287 (2010).
228. Curcio D, Vargas SW, Ugarte Ubiergo S et al. Tigecycline treatment of critically ill patients: The Latin user experience. Curr. Clin. Pharmacol. 6(1), 18-25 (2011).
229. Humphries RM, Kelesidis T, Dien Bard J, Ward KW, Bhattacharya D, Lewinski MA. Successful treatment of pan-resitant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. J. Med. Microbiol. 59, 1383-1386 (2010).
230. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob. 8, 18 (2009).
231. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-b-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53(5), 1868-1873 (2009).
232. Pournaras S, Vrioni G, Neou E et al. Activity of tigecycline alone and in combimation with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob. Agents 37(3), 244-247 (2011).
233. Nguyen M, Eschenauer GA, Bryan M et al. Carbapenem resistant Klebsiella pneumoniae bacteremia: Factors correlated with clinical and microbiologic outcomes. Diagn. Microbiol. Infect. Dis. 67, 180-184 (2010).
234. Lee J, Patel G, Huprikar S, Calfee DP. Decreased susceptibility to polimixin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol. 47, 1611-1612 (2009).
235. Endimiani A, Patel G, Hujer KM et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonscusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother. 54, 526-529 (2010).
236. Popovic M, Steinort D, Pillai S et al. Antimicrobial susceptibility of gram negative non urinary bacteria to fosfomycin and other antimicrobials. Future Microbiol. 5, 961-970 (2010).
237. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes LD, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram positive and Gram negative bacteria. Eur. J. Clin. Pharmacol. 66, 359-368 (2010).
238. Matzi V, Lindenmann J, Porubsky C et al. Extracellular concentration of fosfomycin in lung tissue of septic patients. J. Antimicrob. Chemother. 65, 995-998 (2010).
239. Michalopoulos A, Virtzili S, Rafailidis P, Chavelelakis G, Damala M, Falagas ME. Intravenous forfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: A prospective evaluation. Clin. Microbiol. Infect. 16, 184-186 (2010).
240. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: A systematic review. J. Antimicrob. Chemother. 62(5), 889-894, (2008).
241. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur. J. Microbiol. Infect. Dis. 26(4), 229-237 (2007). (Pubitemid 46572029)
242. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Practices Committee. Management of multidrug-resistant organisms in health care settings. Am. J. Infect. Control 35, S165-193 (2007). (Pubitemid 350225593)
243. Tacconelli E. Screening and isolation for infection control. J. Hosp. Infect. 73, 371-377 (2009).
244. Binkley S, Fishman NO, La Rosa LA et al. Comparison of unit-specific and hospital-wide antibiograms: Potential implications for selection of empirical antimicrobial therapy. Infect. Control Hosp. Epidemiol. 27(7), 682-687 (2006). (Pubitemid 44271948)
245. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA Guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect. Control Hosp. Epidemiol. 24, 362-386 (2003). (Pubitemid 36612323)
246. Lucet JC, Grenet K, Armand-Lefevre L et al. High prevalence of carriage of methicillin resistant Staphylococcus aureus at hospital admission in elderly patients: Implications for infection control strategies. Infect. Control Hosp. Epidemiol. 26, 121-126 (2005). (Pubitemid 40445014)
247. Ostrowsky BE, Trick WE, Sohn AH et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N. Engl. J. Med. 344(19), 1427-1433 (2001). (Pubitemid 32402099)
248. Huang SS, Rifas-Shiman SL, Warren DK et al. Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J. Infect. Dis. 195, 330-338 (2007). (Pubitemid 46146109)
249. Patel M, Weinheimer JD, Waites KB, Baddley JW. Active surveillance to determine the impact of methicillin-resistant Staphylococcus aureus colonization on patients in intensive care units of a veterans affairs medical center. Infect. Control Hosp. Epidemiol. 29, 503-509 (2008). (Pubitemid 351918028)
250. Weber SG, Huang SS, Oriola S et al. Legislative mandaes for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Position statement from the Joint SHEA and APIC task force. Am. J. Infect. Control. 35(2), 73-85 (2007).
251. McGinigle KL, Gourlay ML, Buchanan IB. The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-related morbidity, mortality and costs: A systematic review. Clin. Infect. Dis. 46, 1717-1725 (2008). (Pubitemid 351706769)
252. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin. Microbiol. Infect. 11, 466-471 (2005). (Pubitemid 40744393)
253. Cooper BS, Stone SP, Kibbler CC et al. Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): Systematic review of the literature. BMJ 329(7465), 533 (2004).
254. Cepeda JA, Whitehouse T, Cooper B et al. Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive care units: Prospective two-centre study. Lancet 365(9456), 295-304 (2005). (Pubitemid 40139106)
255. Nijssen S, Bonten MJ, Weinstein RA. Are active microbiological surveillance and subsequent isolation needed to prevent the spread of methicillin-resistant Staphylococcus aureus? Clin. Infect. Dis. 40, 405-409 (2005). (Pubitemid 40216509)
256. Diekema DJ, Edmond MB. Look before you leap: Active surveillance for multidrug-resistant organisms. Clin. Infect. Dis. 44, 1101-1107 (2007). (Pubitemid 46580282)
257. Harris AD, Furuno JP, Roghman MC et al. targeted surveillance of methicillin-resistant Staphylococcus aureus and its potential use to guide empiric antibiotic therapy. Antimicrob. Agents Chemother. 54, 3143-3148 (2010).
258. Strausbaugh LJ, Siegel JD, Weinstein RA. Preventing transmission of multidrug-resistant bacteria in health care settings: A tale of 2 guidelines. Clin. Infect. Dis. 42, 828-835 (2006). (Pubitemid 43363941)
259. Santos RP, Mayo TW, Siegel JD. Active surveillance cultures and contact precautions for control of multidrug-resistant organisms: Ethical considerations. Clin. Infect. Dis. 47, 110-116 (2008). (Pubitemid 351920597)
260. Harbarth S, Frankhauser C, Schrenzel J et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 299(10), 1149-1157 (2008). (Pubitemid 351398429)
261. Carroll MC. Rapid diagnostics for methicillin-resistant Staphylococcus aureus: Current status. Mol. Diagn. Ther. 12, 15-24 (2008).
262. French GL. Methods for screening for methicillin-resistant Staphylococcus aureus carriage. Clin. Microbiol. 15(Suppl. 7), 10-16 (2009).
263. Tacconelli E, De Angelis G, de Waure C, Cataldo MA, La Torre G, Cauda R. Rapid screening tests for methicillin-resistant Staphylococcus aureus at hospital admission: Systematic review and meta-analysis. Lancet Infect. Dis. 9, 546-554 (2010).
264. Stamper PD, Cai M, Lema C, Eskey K, Carroll KC. Comparison of the BD GeneOhm VanR assay to culture for identification of vancomycin-resistant enterococci in rectal and stool specimens. J. Clin. Microbiol. 45, 3360-3365 (2007). (Pubitemid 47585662)
265. Haber M, Levin BR, Kramarz P. Antibiotic control of antibiotic resistance in hospitals: A simulation study. BMC Infect. Dis. 10, 254 (2010).
266. Furuno JP, Perencevich EN, Johnson JA et al. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci co-colonization. Emerg. Infect. Dis. 11, 1539-1544 (2005). (Pubitemid 41384339)
267. Han SH, Chin BS, Lee HS et al. Recovery of both vancomycin.resistant enterococci and methicillin-resistant Staphylococcus aureus from culture of a single clinical specimen from colonized or infected patients. Infect. Control Hosp. Epidemiol. 30(2), 130-138 (2009).
268. Larson EL, Cohen B, Ross B, Behta M. Isolation precautions for methicillin-resistant Staphylococcus aureus: Electronic surveillance to monitor adherence. Am. J. Crit. Care 19, 16-26 (2010).
269. Pittet D, Hugonnet S, Harbarth S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Program. Lancet 356, 1307-1312 (2000).
270. Grayson ML, Jarvie LJ, Martin R et al. Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. Med. J. Aust. 188(11), 633-640 (2008).
271. Pessoa-Silva CL, Hugonnet S, Pfister R et al. Reduction of health care associated infection risk in neonatos by successful hand hygiene promotion. Pediatrics 120(2), e382-e390 (2007). (Pubitemid 47219489)
272. Rodriguez-Bano J, Garcia L, Ramirez E et al. Long-tertm control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. Am. J. Infect. Control 37(9), 715-722 (2009).
273. Longtin Y, Sax H, Allegranzi B et al. Hand Hygiene. N. Engl. J. Med. 364, e24 (2011).
274. Sax H, Allegranzi B, Uckay I et al. My five moments for hand hygiene: A user-centred design approach to understand, train, monitor and report hygiene. J. Hosp. Infect. 67, 9-21 (2007). (Pubitemid 47377724)
275. Sroka S, Gastmeier P, Meyer E. Impact of alcohol hand-rub use on methicillin-resistant Staphylococcus aureus: An analysis of the literature. J. Hosp. Infect. 74(3), 204-211 (2010).
276. Harbarth S, Pittet D. Infection prevention research in Europe: Recent advances and future priorities. Infect. Control Hosp. Epidemiol. 31(Suppl. 1), S11-S13 (2010).
277. Duckro AN, Blom DW, Lyle EA, Weinstein RA, Hayden MK. Transfer of vancomycin-resistant enterococci via health care worker hands. Arch. Intern. Med. 165(3), 302-307 (2005). (Pubitemid 40216283)
278. Huang R, Mehta S, Weed D, Price CS. Methicillin-resistant Staphylococcus aureus survival on hospital fomites. Infect. Control Hosp. Epidemiol. 27(11), 1267-1269 (2006). (Pubitemid 44807477)
279. Williams C, Davis DL. Methicillin-resistant Staphylococcus aureus fomite survival. Clin. Lab. Sci. 22(1), 34-38 (2009).
280. Marchaim D, Navon-Venezia S, Schwartz D et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J. Clin. Microbiol. 45(5), 1551-1555 (2007). (Pubitemid 46762412)
281. Gasink LB, Singer K, Fishman NO et al. Contact isolation for infection in hospitalized patients: Is patient satisfaction affected? Infect. Control Hosp. Epidemiol. 29(3), 275-278 (2008). (Pubitemid 351269195)
282. West TE, Guerry C, Hiott M, Morrow N, Ward K, Salgado CD. Effect of targeted surveillance for control of methicillin-resistant Staphylococcus aureus in a community hospital system. Infect. Control Hosp. Epidemiol. 27(3), 233-238 (2006).
283. Conterno LO, Shymanski J, Ramotar K et al. Real-time polymerase chain reaction detection of methicilin-resistant Staphylococcus aureus: Impact on nosocomial transmission and costs. Infect. Control Hosp. Epidemiol. 28(10), 1134-1141 (2007). (Pubitemid 47580455)
284. Coia JE, Duckworth GJ, Edwards DI et al. Guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J. Hosp. Infect. 63S, S1-S44 (2006).
285. Tacconelli E. Methicillin-resistant Staphylococcus aureus: Source control and surveillance organization. Clin. Microbiol. Infect. 15(Suppl. 7), 31-38 (2009).
286. Gould IM, MacKenzie FM, MacLennan G, Pacitti D, Watson EJ, Noble DW. Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an intensive care unit. Int. J. Antimicrob. Agents 29(5), 536-543 (2007). (Pubitemid 46578190)
287. Sandri AM, Delarosa MG, Ruschel de Alcantara L, da Silva Elias L, Zavascki AP. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: Role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect. Control Hosp. Epidemiol. 27(2), 185-187 (2006). (Pubitemid 43384766)
288. Simor AE, Phillips E, McGeer A et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin and rifampicin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin. Infect. Dis. 44(2), 178-185 (2007). (Pubitemid 46079977)
289. Vernon MO, Hayden MK, Trick WE et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: The effectiveness of source control to reduce the bioburden of vanomycin-resistant enterococci. Arch. Intern. Med. 166(3), 306-312 (2006). (Pubitemid 43244318)
290. Albrich WC, Harbarth S. Health-care workers: Source, vector or victim of MRSA? Lancet Infect. Dis. 8(5), 289-301 (2008). (Pubitemid 351615756)
291. Simpson AH, Dave J, Cookson B. The value of routine screening of staff for MRSA. J. Bone Joint Surg. Br. 89(5), 565-566 (2007). (Pubitemid 46958759)
292. Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection. J. Hosp. Infect. 73(4), 378-385 (2009).
293. Trillis F 3rd, Eckstein EC, Budavich R, Pultz MJ, Donskey CJ. Contamination of hospital curtains with healthcare-associated pathogens. Infect. Control Hosp. Epidemiol. 29(1), 1074-1076 (2008).
294. Hardy KJ, Oppenheim BA, Gossain S, Gao F, Hawkey PM. A study of the relantionship between environmental contamination with methicillin-resistant Staphylococcus aureus (MRSA) and patients acquisition of MRSA. Infect. Control Hosp. Epidemiol. 27(2), 127-132 (2006). (Pubitemid 43384758)
295. De Lassence A, Hidri N, Timsit JF et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin. Infect. Dis. 42(2), 170-178 (2006). (Pubitemid 43054186)
296. Hayden MK, Bonten MJ, Blom DW, Lyle EA, van de Vijver DA, Weinstein RA. Reduction in acquisition of vanomycin-resistant enterococcus after enforcement of routine environmental cleaning measures. Clin. Infect. Dis. 42(11), 1552-1560 (2006).
297. Hayden MK, Blom DW, Lyle EA, Moore CG, Weinstein RA. Risk of hand or glove contamination after contact with patients colonized with vancomycin-resistant enterococcus or the colonized patients environment. Infect. Control Hosp. Epidemiol. 29(2), 149-154 (2008). (Pubitemid 351276884)
298. Fishman N. Antimicrobial stewardship. Am. J. Med. 119, S53-S61 (2006). (Pubitemid 43776138)
299. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J. Antimicrob. Chemother. 61, 26-38 (2008).
300. Lodise TP, Miller C, Patel N, Graves J, McNutt LA. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates. Infect. Control Hosp. Epidemiol. 28, 959-965 (2007). (Pubitemid 47218276)
301. MacAdam H, Zaoutis TE, Gasink LB, Bilker WB, Lautenbach E. Investigating the association between antibiotic use and antibiotic resistance: Impact of different methods of categorising prior antibiotic use. Int. J. Antimicrob. Agents 28, 325-332 (2006). (Pubitemid 44402991)
302. D'Agata EMC, Cataldo MA, Cauda R, Tacconelli E. The importance of addressing multidrug resistance and not assumine single-drug resistance in case-control studies. Infect. Control Hosp. Epidemiol. 27(7), 670-674 (2006). (Pubitemid 44271946)
303. Tacconelli E, De Angelis G, Cataldo MA et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: A hospital population-based study. Antimicrob. Agents Chemother. 53(10), 4264-4269 (2009).
304. Owens RC, Rice L. Hospital-based strategies for combating resistance. Clin. Infect. Dis. 42, S173-S181 (2006).
305. Pulcini C, Defres S, Aggarwal I, Nathwani D, Davey P. Design of a "day 3 bundle" to improbe the reassesment of inpatient empirical antibiotic prescriptions. J. Antimicrob. Chemother. 61, 1384-1388 (2008). (Pubitemid 351753611)
306. Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit implementation of a computerized antibiotic decision support system. J. Antimicrob. Chemother. 65, 1062-1069 (2010).
307. Davey P, Brown E, Fenelon L et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg. Infect. Dis. 12(2), 211-216 (2006).
308. Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: Maximizing clinical outcomes and minimizing selection of resistant organisms. Clin. Infect. Dis. 42(Suppl. 2), 4-16 (2006).
309. Bergstrom CT, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc. Natl Acad. Sci. USA 101(36), 13285-13290 (2004). (Pubitemid 39209657)
310. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin. Infect. Dis. 43(Suppl. 2), S82-S88 (2006). (Pubitemid 44267145)
311. Zillich AJ, Sutherland JM, Wilson SJ, Diekema DJ, Ernst EJ, Vaughn TE. Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. Infect. Control Hosp. Epidemiol. 27(10), 1088-1095 (2006). (Pubitemid 44670986)
312. Drew RH. Antimicrobial stewardship programs: How to start and steer a successful program. J. Manag. Care Pharm. 15(2), S18-S23 (2009).
313. Patel D, MacDougall C. How to make antimicrobial stewardship work: Practical considerations for hospitals of all sizes. Hosp. Pharm. 45(11 Suppl. 1), S10-S18 (2010).
314. Goff DA. Antimicrobial stewardship: Bridging the gap between quality care and cost. Curr. Opin. Infect. Dis. 24(Suppl. 1), S11-S20 (2011).
315. Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients exposure to antibiotics in intensive care units (PRORATA trial): Has been tested in a multicentre randomised controlled trial. Lancet 375, 463-474 (2010).